Acute and chronic toxicities of carcinoma cervix CTRT
Reading File
Finding Sources
Finding Sources
Searching PubMed
"cervical cancer" AND "chemoradiotherapy" AND "toxicity"
Finding Sources
Finding Sources
Reading Article
PMID: 37979708
Finding Sources
Finding Sources
Searching the Web
carcinoma cervix CTRT concurrent chemoradiotherapy acute chronic toxicity management
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC7712236
Finding Sources
Searching the Web
cervical cancer CTRT late toxicity bowel bladder vaginal stenosis fistula grading CTCAE
Searching PubMed
"cervical cancer" AND "late toxicity" AND "chemoradiation"
Reading Web Page
https://www.appliedradiationoncology.com/articles/late-effec…
I now have comprehensive information to deliver a detailed, well-organized answer. Let me compile it.
Acute and Chronic Toxicities of Carcinoma Cervix CTRT (Concurrent Chemoradiotherapy)
Standard treatment for locally advanced carcinoma cervix (FIGO IIB-IVA) is concurrent chemoradiotherapy (CTRT) - weekly cisplatin (40 mg/m²) with external beam radiotherapy (EBRT) followed by brachytherapy (BT). Up to 84% of patients experience some form of acute radiation toxicity during this treatment.
ACUTE TOXICITIES (within 90 days of treatment initiation)
Acute toxicity results from injury to rapidly proliferating cells in normal tissues.
1. Hematological Toxicity
The most common form due to large pelvic bone marrow irradiation combined with cisplatin myelosuppression.
| Toxicity | Details |
|---|---|
| Leukopenia/Neutropenia | Most frequent; Grade 3-4 in ~20-30% patients; increases infection risk |
| Anemia | Worsens pre-existing disease-related anemia; may require transfusion |
| Thrombocytopenia | Less common but can delay treatment |
| Cisplatin effect | Additive myelosuppression; nadir around day 10-14 post-cycle |
CTCAE Grading:
- Grade 1: ANC 1500-1900/mm³
- Grade 2: ANC 1000-1499/mm³
- Grade 3: ANC 500-999/mm³ (dose-limiting)
- Grade 4: ANC <500/mm³ (treatment hold)
Risk factors: Higher FIGO stage, >4 cycles of chemotherapy, low baseline counts.
2. Gastrointestinal (GI) Toxicity
Very common due to small bowel and large bowel included in pelvic field.
| Toxicity | Incidence | Features |
|---|---|---|
| Nausea/Vomiting | Very common, especially with cisplatin | Occurs within hours of cisplatin; prophylactic antiemetics mandatory |
| Diarrhea | 50-80% patients | Loose stools, cramping; peaks at 3-4 weeks |
| Proctitis | Common | Tenesmus, mucus per rectum, rectal pain, urgency |
| Enteritis | Moderate frequency | Abdominal cramps, bloating |
CTCAE Grading (Diarrhea):
- Grade 1: <4 stools/day above baseline
- Grade 2: 4-6 stools/day; IV fluids <24h
- Grade 3: ≥7 stools/day; IV fluids ≥24h; hospitalization
- Grade 4: Life-threatening consequences
Management: Loperamide, hydration, low-residue diet, temporary treatment breaks for Grade 3-4.
3. Genitourinary (GU) Toxicity
| Toxicity | Features |
|---|---|
| Cystitis | Dysuria, frequency, urgency, microscopic hematuria; dysuria most common |
| Urethritis | Burning micturition |
| Urinary frequency | Bladder irritation from EBRT + BT |
CTCAE Grading (Cystitis):
- Grade 1: Asymptomatic; microscopic hematuria
- Grade 2: Symptomatic; medical intervention; gross hematuria
- Grade 3: Transfusion/IV meds indicated; invasive intervention needed
- Grade 4: Life-threatening (e.g., obstructive uropathy)
4. Dermatological Toxicity
| Toxicity | Features |
|---|---|
| Radiation dermatitis | Erythema, dry/moist desquamation in perineal/groin region |
| Skin fold reactions | More severe in obese patients |
| Radiation recall | If prior chemotherapy given |
CTCAE Grading:
- Grade 1: Faint erythema, dry desquamation
- Grade 2: Moderate-intense erythema, moist desquamation in folds
- Grade 3: Moist desquamation outside folds, pitting edema
- Grade 4: Skin necrosis/ulceration, full-thickness dermis loss
5. Vaginal/Mucosal Toxicity (Acute)
- Vaginitis/mucositis: Erythema, discharge, pain during EBRT and BT
- Vaginal discharge: Common; may be bloody from tumor response
- Graded as vaginal mucositis by CTCAE
6. Cisplatin-Specific Acute Toxicities
| Toxicity | Details |
|---|---|
| Nephrotoxicity | Creatinine rise; requires pre/post-hydration and monitoring |
| Ototoxicity | High-frequency hearing loss; cumulative |
| Peripheral neuropathy | Uncommon at weekly low-dose (40 mg/m²) but can occur |
| Electrolyte disturbances | Hypomagnesemia, hypokalemia; require replacement |
7. Fatigue
Near-universal; multifactorial (anemia, treatment burden, pain, insomnia).
CHRONIC/LATE TOXICITIES (months to years after treatment)
Late toxicity results from fibrosis, vascular injury, and gradual changes in slowly dividing tissues - often irreversible.
1. Gastrointestinal Late Toxicity
| Toxicity | Incidence/Features |
|---|---|
| Chronic radiation proctitis | Rectal bleeding, tenesmus, urgency; 5-15% Grade 2+; due to rectal mucosal ischemia and telangiectasia |
| Radiation enteritis | Malabsorption, diarrhea, abdominal pain; small bowel most radiosensitive |
| Bowel obstruction | Due to adhesion, stricture, fibrosis; may require surgery |
| Rectal stricture | Narrowing causing constipation, obstruction |
| Recto-vaginal fistula | Abnormal communication; Grade 4 toxicity; requires diversion |
| Fecal incontinence | Due to sphincter damage; surgical management limited by poor wound healing |
| Secondary rectal malignancy | RR 1.43 (95% CI 1.18-1.72) vs general population |
Key dose predictor: Rectal EQD2 D2cc (from BT) and V30, V40, V55 Gy (from EBRT) strongly predict GI toxicity (per systematic review, PMID 37979708).
2. Genitourinary Late Toxicity
| Toxicity | Incidence/Features |
|---|---|
| Radiation cystitis | Hematuria, urgency, frequency; telangiectasia formation |
| Hemorrhagic cystitis | Gross hematuria; may require hyperbaric O₂, intravesical agents |
| Bladder fibrosis/contracture | Reduced bladder capacity; urgency, frequency |
| Bladder ulceration | Persistent non-healing tissue; Grade 3-4 <3% with modern techniques |
| Vesico-vaginal fistula | Urinary incontinence; requires surgical repair; higher risk with obesity, smoking |
| Ureterovaginal fistula | Less common |
| Ureteric stricture | Hydronephrosis, renal impairment |
Risk factors for GU complications: Obesity, smoking, anticoagulant use, higher bladder D2cc dose from brachytherapy.
3. Vaginal/Sexual Late Toxicity
| Toxicity | Incidence/Features |
|---|---|
| Vaginal stenosis | Most common late vaginal effect; 2.5-88% incidence (wide variation); shortening + narrowing of vaginal vault |
| Vaginal dryness/atrophy | Due to ovarian failure + direct mucosal damage |
| Dyspareunia | Major QOL issue; >50% women report sexual dysfunction |
| Vaginal ulceration | Non-healing ulcers; risk with high point doses at brachytherapy |
| Vaginal adhesions | Bilateral walls adhere together |
Prevention: Regular use of vaginal dilators is the primary treatment and prevention strategy for stenosis. Topical estrogen helps with dryness/atrophy.
Risk factors: Advanced tumor, higher vaginal RT dose, lack of dilator compliance, concomitant chemotherapy, older age.
4. Bony/Musculoskeletal Late Toxicity
| Toxicity | Features |
|---|---|
| Insufficiency/Stress fractures | Sacrum, pubic rami most common; incidence 2-10%; presents as pelvic pain; MRI diagnostic |
| Hip avascular necrosis | Less common |
| Osteoporosis/osteopenia | Due to radiation + ovarian failure (premature menopause) |
Risk factors: Low pre-treatment bone density is predictive (per PMID 37979708).
5. Lymphedema
- Lower limb lymphedema in 10-25% patients due to pelvic lymph node irradiation
- Worse with extended-field radiation or para-aortic nodal treatment
- Requires compression therapy, physiotherapy
6. Secondary Malignancy
- Increased risk of bladder cancer, rectal cancer, uterine sarcoma in the irradiated field (latency: 5-20 years)
- Rectal cancer RR: 1.43; no increased ovarian cancer risk with pelvic RT
7. Hormonal/Ovarian Effects
- Premature menopause in pre-menopausal women (ovarian dose during pelvic RT)
- Hot flashes, mood changes, osteoporosis risk, cardiovascular risk
- Ovarian transposition (oophoropexy) before EBRT can preserve function in selected cases
8. Renal/Cisplatin Late Effects
- Chronic nephropathy: GFR decline with cumulative cisplatin
- Persistent peripheral neuropathy: Especially with higher cumulative doses
- Hypomagnesemia: May persist long-term
Summary Table
| System | Acute | Chronic/Late |
|---|---|---|
| Hematological | Leukopenia, anemia, thrombocytopenia | Rare persistent cytopenias |
| GI | Nausea, diarrhea, proctitis | Proctitis, enteritis, fistula, stricture, secondary malignancy |
| GU | Cystitis, dysuria, frequency | Hemorrhagic cystitis, fibrosis, fistula, ureteric stricture |
| Vaginal | Mucositis, discharge | Stenosis, dryness, dyspareunia, adhesions |
| Skin | Dermatitis, desquamation | Fibrosis, telangiectasia, pigmentation |
| Bone | - | Insufficiency fractures, osteoporosis |
| Lymphatics | - | Lymphedema |
| Hormonal | - | Premature menopause |
| Renal/Cisplatin | Nephrotoxicity, electrolytes | Chronic nephropathy, neuropathy |
| Secondary malignancy | - | Rectal, bladder cancer |
Dose Constraints (QUANTEC/GEC-ESTRO) to Minimize Late Toxicity
| Organ at Risk | Key Constraint |
|---|---|
| Rectum (EBRT) | V40 Gy < 40%, V55 Gy < 20% |
| Rectum (BT) | D2cc EQD2 ≤ 70-75 Gy |
| Bladder (BT) | D2cc EQD2 ≤ 90 Gy |
| Bowel/Sigmoid (BT) | D2cc EQD2 ≤ 70-75 Gy |
| Vaginal point dose | Linked to stenosis/fistula risk |
Modern image-guided adaptive brachytherapy (IGABT) has significantly reduced Grade 3+ late toxicity compared to point-based dosimetry. The systematic review by Corbeau et al. (2024) confirms that brachytherapy-related dose-volume parameters (especially rectal/bowel EQD2 D2cc) are the strongest predictors of GI toxicity, and vaginal dose metrics predict GU/vaginal toxicity (PMID 37979708).
Key Risk Factors for Toxicity
- Higher FIGO stage (bulkier tumor, more tissue in field)
- Higher cumulative radiation dose
- Conventional EBRT vs. IMRT (IMRT reduces bowel and bladder dose)
- Number of cisplatin cycles completed (>4 cycles increases risk)
- Patient factors: Obesity, smoking, diabetes, pre-existing bowel/bladder disease, low bone density, IBD
- Total reference air kerma (TRAK) in brachytherapy
- Extent of vaginal involvement at diagnosis
This is a shared conversation. Sign in to Orris to start your own chat.